Virtual Library
Start Your Search
Minhua Ye
Author of
-
+
P1.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 947)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.15-32 - Real World EGFR Mutation Profile from 1699 Non-Small Cell Lung Cancer Patients in Eastern China (ID 12526)
16:45 - 18:00 | Author(s): Minhua Ye
- Abstract
Background
The EGFR mutation frequency and mutation types had significant geographic differences. The purpose of this study was to evaluate prevalence, clinical characteristic in eastern China which has not been reported.
a9ded1e5ce5d75814730bb4caaf49419 Method
From March 2016 to March 2018 who were newly diagnosed or postoperative recurrence NSCLC received EGFR mutation detect were included analysis. Commercially available ARMS-PCR kits were used to detect EGFR mutations.
4c3880bb027f159e801041b1021e88e8 Result
A total of 1699 consecutive NSCLC patients included in our study. The median age was 64 years (range 23-91), with 892 (52.5%) were male and 807 (47.5%) male. There were 852 (50.2%) with EGFR mutations out of 1699 patients in the total population. EGFR mutations were more frequent in female (64.9%) patients than in males (36.8%). Considering the frequency of mutations according to histology, adenocarcinomas (835/1495, 55.9% ) show mutations more often than squamous carcinoma (4/142, 2.82%), other NSCLC histology (13/62, 21.0%). The rate of EGFR mutation in total was lower in biopsy specimen (246/613, 40.1%) than in surgical specimen (557/993, 56.1%) or cytology specimen(49/93, 52.69%). A total of 755 (88.6%) harboring a common EGFR mutation were identified: among the 755, the most EGFR mutation type was the point mutation L858R at 21 exon (49.5%), followed by exon 19 deletion (39.1%). Ninety-seven (11.48%) patients harboring uncommon EGFR mutation, the exon 20 INS (34.0%) was the most frequently observed mutation among the uncommon EGFR mutations. The detailed EGFR mutation type were show in table1.
8eea62084ca7e541d918e823422bd82e ConclusionTable1. The detailed EGFR mutation type
Mutation type
Case number
Percentage of all cases
Percentage of uncommon mutation
common mutation
L858R
422
49.53%
19-del
333
39.08%
uncommon mutation
20-Ins
33
3.87%
34.0%
L858R/T790M
18
2.11%
18.6%
G719X
14
1.64%
14.4%
L861Q
11
1.29%
11.3%
G719X/S768I
5
0.59%
5.2%
L858R+S768I
5
0.59%
5.2%
S768I
4
0.47%
4.1%
19-del/T790M
3
0.35%
3.1%
G719C
1
0.12%
1.0%
L858R/19-del
1
0.12%
1.0%
L858R/20-Ins
1
0.12%
1.0%
T790M
1
0.12%
1.0%
EGFR: Epidermal growth factor receptor.
In our eastern China cohort, the most common EGFR mutation was L858R, differing from previous reported data in Asian population describing 19 deletion was the most common EGFR mutation. The frequency of EGFR mutations in biopsy specimen population was lower than both in surgical specimen and cytology specimen.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P3.11 - Screening and Early Detection (Not CME Accredited Session) (ID 977)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
-
+
P3.11-26 - Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer from a Single-Institution in China (ID 12841)
12:00 - 13:30 | Author(s): Minhua Ye
- Abstract
Background
Lung cancer screening using low-dose computed tomography (LDCT) has been reported to reduce lung cancer-specific mortality for smokers at high risk in patients of the United States. However, there are very few LDCT screening results from Chinese patients. We here report the screening findings at the initial round of LDCT screening program from a single-institution population-based cohort in China.
a9ded1e5ce5d75814730bb4caaf49419 Method
We conducted a retrospective study of a single-institution population-based LDCT screening program for lung cancer. Patients participated LDCT in Taizhou Hospital of Enze Medical Center were eligible. All noncalcified nodules with long-axis diameters of 4mm or greater in the axial plane were considered to be positive for potential lung cancer according to NLST definition. If more than three nodules were found, one dominant nodules were selected for this analysis.
4c3880bb027f159e801041b1021e88e8 Result
From July 2017 through December 2017, a total of 8611 participants with LDCT screening were included in this report. A total of 78 participants with history of cancer and 437 participants were follow-up procedures were excluded in this analysis. Of the remaining 8096 participants, the median age was 51 years (range, 16-97 years). A total of 1516 (18.8%) participants were younger than 40 years, 5264 (65.2%) were 40-64 years and 1316 (16.3%) were greater than 64 years. The total proportion of positive nodules was 21.8%, slightly higher in females (535/2258, 23.7%) than males (1233/5838, 21.1%). Lung cancer was diagnosed in 26 participants (0.32%) (11 males and 14 females) of the 1768 positive nodules. The comprehensive demographics of 26 lung cancer patients (included one patients with multiple metastases tumor from pancreas) is shown table 1.
Table 1 Comprehensive demographics of 26 lung cancer patientsNo.
Sex
Age
(y)
Smoking
Type of nodules
Histology
Type of EGFRm
TNM
Treatment
1
M
70
Never
8mm GGN, RUL
ADC in situ
Wild
pT1isN0M0
Wedge resection
2
M
47
Current,
40 pack-year
16mm solid, RUL
ADC
19-del
pT1aN0M0
Lobectomy
3
M
70
Never
Multiple nodules;
12mm solid, RLL
Metastatic ADC from pancreas
unknown
pT1bN0M0
without
4
M
53
Current,
60 pack-year
21mm sub-solid, LLL
ADC
unknown
pT1cN0M0
Lobectomy
5
M
49
Never
6mm GGO, RLL
ADC
L858R
pT1aN0M0
Wedge resection
6
M
62
Former,
45 pack-year
30mm, LLL
SCC
unknown
cT2aN2M0
chemotherapy
7
M
62
Former,
24pack-year,
32mm solid, RLL
ADC
19-del
pT4N0M0
Lobectomy
8
F
44
Never
12mm GGO, LUL
ADC
unknown
pT1bN0M0
Segmental Resection
9
F
68
Never
8mm GGO,RML
ADC
unknown
pT1aN0M0
Lobectomy
10
M
74
Current,
60 pack-year
14mm solid, RUL
ADC
L858R
pT1aN0M0
Wedge resection
11
M
74
Former,
40 pack-year
15mm sub-solid, LLL
SCC
unknown
pT1bN2M0
Lobectomy
12
F
55
Never
12mm GGN, RUL
ADC
unknown
pT1aN0M0
Lobectomy
13
F
64
Never
11mm GGO,RUL
8mm GGO, RUL
ADC
ADC
Wild
pT3N0M0
Lobectomy
14
F
78
Never
18mm solid, RLL
ADC
19-del
cT1bN0M0
Gefitinib
15
F
67
Never
14mm GGO, RUL
12mm GGO, RUL
ADC;
ADC
unknown
pT3N0M0
Lobectomy
16
F
73
Never
18mm GGO, LUL
ADC
unknown
pT1bN0M0
Wedge resection
17
M
75
Never
10mm sub-solid, RUL
ADC
unknown
pT1aN0M0
Lobectomy
18
M
71
Current,
60 pack-year
30mm solid, LLL
NSCLC
unknown
cT2aN2M
Lobectomy
19
F
60
Never
8mm solid, RLL
ADC
19-del
pT1aN0M0
Lobectomy
20
F
78
Never
17mm solid, RUL
ADC
L858R
pT1bN0M0
Wedge resection
21
F
56
Never
11mm GGN,RUL
ADC
unknown
pT1bN0M
Lobectomy
22
F
58
Never
13mm solid, RUL
ADC
L858R
pT1bN0M0
Lobectomy
23
F
46
Never
13mm sub-solid, LUL
ADC
Wild
pT1bN0M0
Lobectomy
24
M
65
Current,
40 pack-year
50mm solid, LUL
SCC
unknown
pT3N0M0
Lobectomy
25
F
67
Never
9mm solid, RUL
5mm solid, RUL
ADC;
ADC in situ
L858R
pT3N0M0
Wedge resection
26
F
47
Never
7mm GGO, RUL
ADC
20-INS
pT1bN0M0
Wedge resection
GGO=Ground-glass opacity; GGN=ground glass density nodule; RML=right middle lobe; RLL=right lower lobe; RUL=right lower lobe; LUL=left upper lobe; LLL=left lower lobe; tis=carcinoma in site; EGFRm= EGFR mutation
8eea62084ca7e541d918e823422bd82e Conclusion
The overall rate of positive nodules is similar to previous reports, and the overall cancer detection rate by LDCT in our cohort was lower than previous reports from others (0.36-3.3%).
6f8b794f3246b0c1e1780bb4d4d5dc53
